Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study.

Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfetano JH, Mychalczak BR, King ME.

Gynecol Oncol. 2005 Jun;97(3):755-63.

PMID:
15913742
2.

Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study.

Fowler JM, Blessing JA, Burger RA, Malfetano JH.

Gynecol Oncol. 2002 May;85(2):311-4.

PMID:
11972393
3.

Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.

Clarke-Pearson DL, Van Le L, Iveson T, Whitney CW, Hanjani P, Kristensen G, Malfetano JH, Beckman RA, Ross GA, Lane SR, DeWitte MH, Fields SZ.

J Clin Oncol. 2001 Oct 1;19(19):3967-75.

PMID:
11579118
4.

Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas.

Ross JS, Sheehan CE, Williams SS, Malfetano JH, Szyfelbein WM, Kallakury BV.

Am J Clin Pathol. 2001 Jul;116(1):122-8.

PMID:
11447742
5.

Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study.

Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, Malfetano JH, Alvarez RD.

J Clin Oncol. 2001 Mar 1;19(5):1275-8.

PMID:
11230468
6.

Villoglandular adenocarcinoma of the endometrium.

Ambros RA, Malfetano JH.

Am J Surg Pathol. 2000 Jan;24(1):155-6. No abstract available.

PMID:
10632501
8.

Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.

Kallakury BV, Ambros RA, Hayner-Buchan AM, Sheehan CE, Malfetano JH, Ross JS.

Int J Gynecol Pathol. 1998 Oct;17(4):320-6.

PMID:
9785132
9.

Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study.

Asbury R, Blessing JA, Buller R, Malfetano JH, Walker J, Sevin BU.

Am J Clin Oncol. 1998 Apr;21(2):145-6.

PMID:
9537200
10.

Extended field radiation and cisplatin for stage IIB and IIIB cervical carcinoma.

Malfetano JH, Keys H, Cunningham MJ, Gibbons S, Ambros R.

Gynecol Oncol. 1997 Nov;67(2):203-7.

PMID:
9367709
11.

Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.

Riben MW, Malfetano JH, Nazeer T, Muraca PJ, Ambros RA, Ross JS.

Mod Pathol. 1997 Aug;10(8):823-31.

PMID:
9267826
12.

Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva.

Cunningham MJ, Goyer RP, Gibbons SK, Kredentser DC, Malfetano JH, Keys H.

Gynecol Oncol. 1997 Aug;66(2):258-61. Review.

PMID:
9264573
13.

Telomerase activity in benign endometrium and endometrial carcinoma.

Brien TP, Kallakury BV, Lowry CV, Ambros RA, Muraca PJ, Malfetano JH, Ross JS.

Cancer Res. 1997 Jul 1;57(13):2760-4.

14.
15.

A phase II trial of edatrexate in previously treated squamous cell cervical cancer: a Gynecologic Oncology Group study.

Broun ER, Iseminger KA, Rose PG, Lentz SL, Malfetano JH, Lincoln S, Mannel R.

Am J Clin Oncol. 1997 Feb;20(1):78-80.

PMID:
9020294
16.
17.
18.

Clinicopathologic features of vulvar squamous cell carcinomas exhibiting prominent fibromyxoid stromal response.

Ambros RA, Malfetano JH, Mihm MC Jr.

Int J Gynecol Pathol. 1996 Apr;15(2):137-45.

PMID:
8786203
19.

A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study.

Malfetano JH, Blessing JA, Homesley HD, Look KY, McGehee R.

Am J Clin Oncol. 1996 Apr;19(2):184-6.

PMID:
8610646
20.

Peripheral infusion ports for central venous access in patients with gynecologic malignancies.

Cunningham MJ, Collins MB, Kredentser DC, Malfetano JH.

Gynecol Oncol. 1996 Mar;60(3):397-9.

PMID:
8774645

Supplemental Content

Loading ...
Support Center